The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Good morning! Meta's elimination of fact-checking opens the door to misogynistic speech, Jane Fraser faces a test at Citi, ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Financial writer recommends buying LifeVantage stock after exceeding Q2/FY2025 expectations with new MindBody GLP-1 System launch.

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

Eli Lilly should become a much bigger money machine with multiple growth drivers in its product lineup and a promising ...

Lilly Grove Special Utilities District has issued a boil water notice for some customers. This notice has been issued due a ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug ...